the effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic hcv genotype-4 patients: a single centre egyptian study
نویسندگان
چکیده
background egypt has one of the highest (16-8%) prevalence rates of hcv infection in the world. approximately 90% of egyptian hcv isolates belong to a single subtype (4a), which responds less successfully to interferon therapy than other subtypes. studies comparing the efficacy and safety of pegifn alfa-2a and pegifn alfa-2b in treatment-naive hcv-infected patients have shown conflicting results. objectives assessing the effects of peginterferon alpha-2a versus peginterferon alpha-2b on the sustained virological response in naive chronic hcv genotype-4 egyptian patients. patients and methods this retrospective study cohort consists of 3718 chronic hcv patients admitted to a large, egyptian medical center. 1985 patients had been treated with peg-ifn alfa-2a plus rbv and 1733 patients with peg-ifn alfa-2b plus rbv between years 2007-2011. efficacy outcomes were sustained virologic response (svr) and treatment discontinuation rates due to serious adverse effects. results the etr & svr in patients treated with pegifn alfa-2a was 64.1% and 59.6% as compared to treatment with pegifn alfa-2b where these parameters were 58.2% and 53.9% respectively (p < 0.05). treatment discontinuation rates, were similar in the two types of pegifn [0.66 (0.37-1.16); p = 0.15]. significant dose reduction was evident with peginterferon alfa-2b (35.3%) than peginterferon alpha-2a (27.3 %) (p < 0.01). patients with lower base line afp and alt were most likely to achieve svr using inf alpha 2-a. conclusions peginterferon alpha-2a has a higher efficacy regarding etr and svr as compared to peginterferon alfa-2b in treatment of naive chronic hcv genotype-4 patients.
منابع مشابه
The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study
BACKGROUND Egypt has one of the highest (16-8%) prevalence rates of HCV infection in the world. Approximately 90% of Egyptian HCV isolates belong to a single subtype (4a), which responds less successfully to interferon therapy than other subtypes. Studies comparing the efficacy and safety of PEGIFN alfa-2a and PEGIFN alfa-2b in treatment-naive HCV-infected patients have shown conflicting result...
متن کاملefficacy and tolerability of peginterferon alpha-2a and peginterferon alpha-2b in iranian patients with chronic hepatitis c
conclusions there was no significant difference in the efficacy of peginterferon-alpha-2a and peginterferon-alpha-2b in iranian patients. physicians might choose the treatment regimen for every individual concerning the differences in side effects of peginterferons. background nearly 0.5% of iranians are infected with hcv. peginterferon-alpha-2a and peginterferon-alpha-2b are the two available ...
متن کاملEfficacy of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV: Interpretation of Results and Future Prospects
I their meta-analysis of the efficacy of peginterferon alfa-2a (PEG-IFN-α2a) or alfa2b (PEG-IFN-α2b) and ribavirin for the treatment of hepatitis C virus (HCV), Alavian et al. (1), analyzing pooled data from 7 studies, conclude that PEG-IFNα2a (with similar safety) is more effective than PEGIFN-α2b. While PEG-IFN alfa-2b with ribavirin is generally considered as the treatment of choice for chro...
متن کاملEfficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
BACKGROUND Nearly 0.5% of Iranians are infected with HCV. Peginterferon-alpha-2a and Peginterferon-alpha-2b are the two available types of interferon for the treatment of hepatitis C. Comparing the results of these two treatments is still a challenge. OBJECTIVES The aim of this study was to compare the results of Peginterferon-alpha-2a and Peginterferon-alpha-2b in Iranian patients with chron...
متن کاملArea-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C.
One reason for dosing a drug by body weight is to reduce interpatient variability in clinical response. This study evaluated the relationship between body weight and drug exposure for peginterferon alpha-2a and peginterferon alpha-2b used in combination with ribavirin for treating patients with chronic hepatitis C. These two products are dosed differently: peginterferon alpha-2a is flat-dosed a...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
hepatitis monthlyجلد ۱۳، شماره ۵، صفحات ۰-۰
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023